New diagnostic tool increases the value of Kancera's ROR cancer treatment

25 June 2012

Kancera and the Karolinska Institute have developed antibodies that permit the development of a diagnostic tool to identify cancer patient response to treatment using Kancera’s ROR inhibitors.

The distinctive properties of these new antibodies are their selectivity between the active (phosphorylated) and inactive (non-phosphorylated) forms of ROR. The new antibodies constitute an important tool in the further development of our ROR inhibitors and potentially also a valuable diagnostic to be used in a future therapy targeting ROR.

About the ROR-project

ROR is a family of receptor tyrosine kinase receptors originally reported to be linked to foetus development and consists of two receptors, ROR1 and ROR2. Today it is also known that ROR receptors play a role also for cancer cells. It has been shown that inhibition of ROR causes certain cancer cells to eliminate themselves through apoptosis.

Since ROR receptors are not present in healthy cells in adults, it is anticipated that a drug targeting ROR will selectively attack the tumour much more forcefully than healthy tissue.

Kancera’s co-founder Professor Håkan Mellstedt has shown that Kancera´s ROR inhibitors are capable of killing cancer cells originating from pancreas and as well as leukemic cells. Professor Mellstedt and other scientists have further shown that ROR is a potential therapeutic target also in prostate, breast and lung cancer.


To top